# Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

> **NCT05781217** · PHASE3 · RECRUITING · sponsor: **Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic** · enrollment: 534 (estimated)

## Conditions studied

- Prostate Cancer
- Salvage Radiotherapy
- Biochemical Recurrence
- Androgen Deprivation Therapy
- Metastases-free Survival

## Interventions

- **DRUG:** triptorelin, goserelin, leuprorelin

## Key facts

- **NCT ID:** NCT05781217
- **Lead sponsor:** Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-14
- **Primary completion:** 2023-12
- **Final completion:** 2032-12
- **Target enrollment:** 534 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05781217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05781217, "Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05781217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*